Dotinurad, a selective UA reabsorption inhibitor, that selectively inhibits URAT1, has recently been developed as a potent uricosuric agent7,15 and is widely used in clinical practice in Japan for the treatment of patients with hyperuricemia. This evidence concerns the gene SLC22A12 and hyperuricemia.